BioCentury | Dec 11, 2020
Emerging Company Profile
Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology
...Rock partner emeritus and SAB member, and Faze co-founder Ronald Vale about repeat expansion disorder pathogenesis.Meyers...